UNASSIGNED: Increased maternal @entity342 exposure during pregnancy programmes a @entity3610 , with @entity209 , in adult female offspring. Other in utero exposures associated with the development of @entity26434 resistance, such as intrauterine growth restriction and exposure to prenatal glucocorticoids, are associated with altered fetal gluconeogenesis. We therefore aimed to assess the effect of maternal androgenisation on the expression of @entity38775 and @entity38776 in the ovine fetus. Pregnant Scottish Greyface @entity742 were treated with twice weekly @entity3033 (TP; 100mg) or vehicle control from day 62 to day102 of gestation. At day 90 and day 112 fetal plasma and liver and kidney tissue was collected for analysis. @entity38775 and @entity38776 expression were analysed by quantitative RT-PCR, immunohistochemistry and western blotting. @entity38775 and @entity38776 were localised to fetal hepatocytes but maternal @entity3800 had no effect on female or male fetuses. @entity38775 and @entity38776 were also localised to the renal tubules and renal @entity38775 (P<0.01) and @entity38776 (P = 0.057) were lower in females after prenatal androgenisation with no change in male fetuses. These tissue and sex specific observations could not be explained by alterations in fetal @entity26434 or @entity701 . The sexual dimorphism may be related to the increase in circulating @entity172 (P<0.01) and @entity251 (P<0.001) in females but not males. The tissue specific effects may be related to the increased expression of @entity70443 (P<0.01) and AR (P<0.05) in the kidney when compared to the fetal liver. After discontinuation of maternal androgenisation female fetal kidney @entity38775 expression normalised. These data further highlight the fetal and sexual dimorphic effects of maternal androgenisation, an antecedent to @entity66 and the plasticity of fetal development.

In an Ovine Model of XXXX ( @entity3610 ) Prenatal @entity3800 Suppress Female Fetal Renal Gluconeogenesis.

@entity3033 :: ('MESH:D043343', 'Chemical') :: ['testosterone propionate'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome (PCOS)-like condition'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity742 :: ('9940', 'Species') :: ['sheep'] @entity66 :: ('MESH:D004194', 'Disease') :: ['adult disease'] @entity70443 :: ('443228(Tax:9940)', 'Gene') :: ['ESR1'] @entity38776 :: ('100037689(Tax:9940)', 'Gene') :: ['G6PC'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity26434 :: ('105613195', 'Gene') :: ['insulin'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic dysfunction'] @entity38775 :: ('100037690(Tax:9940)', 'Gene') :: ['PEPCK'] @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens']
@entity3610 :: (MESH:D011085,Disease) :: ['Polycystic Ovary Syndrome']
